A new option for radioimmunotherapy in lymphoma patients

A new treatment option for patients with relapsing follicular, mantle cell and other indolent B-cell lymphomas has been determined safe and feasible by researchers exploring the potential of a low energy beta-emitter radiopharmaceutical. According to data from the study “Radioimmunotherapy with 177Lu-DOTA-Rituximab: Final Results of a Phase I/II Study in 31 Patients with Relapsing Follicular, Mantle Cell, and Other Indolent B-Cell Lymphomas” (link),  published in the July issue of The Journal of Nuclear Medicine, the use of 177Lu-DOTA-rituximab as a radioimmunotherapy results in a high rate of tumor response while using less radiation than current therapies. According to the authors, although 90Y ibritumomab tiuxetan—Zevalin—was introduced shortly after they started the study, they felt it was important to do clinical experiments with other radionuclides.

Sources: Society of Nuclear Medicine, MolecularImaging

About Tablón de Radiofarmacia

https://www.linkedin.com/profile/view?id=165365818&locale=es http://www.radiopharmacy.net/jlgp.html https://www.researchgate.net/profile/Jesus_Gomez_Perales/publications
This entry was posted in News. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s